Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Rank in Stocks #14767
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Share Price
$16.85
Last synced: 2023-07-07
Market Cap
$393.50M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CH
Trade VectivBio Holding AG (VECT)

Category

Stock price history for VectivBio Holding AG (VECT)
Highest end of day price: $16.72 on 2023-07-01

Lowest end of day price: $16.68 on 2021-04-01
Stock price history of VectivBio Holding AG from 2021 to 2026
Annual Stock Price Performance
Year Performance
2023 96.64%
2022 112.95%
2021 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$749.64 5.07%
CH